


bsm-61135R**[Primary Antibody]****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

CD11c Recombinant Rabbit mAb**— DATASHEET —****Host:** Rabbit**Isotype:** IgG**Clonality:** Recombinant**CloneNo.:** C9E2**GeneID:** 3687**SWISS:** P20702**Target:** CD11c**Immunogen:** A synthesized peptide derived from human CD11c: 1100-1163.**Purification:** affinity purified by Protein A**Storage:** 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol. Store at 4°C for short term. Store at -20°C for long term. Avoid repeated freeze/thaw cycles.**Background:** Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R. Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL.**Applications:** **WB** (1:500-2000)
IHC-P (1:100-200)
IHC-F (1:100-200)
IF (1:100-200)
ICC/IF (1:50-200)
IP (1:20-50)**Reactivity:** Human**Predicted
MW.:** 128**Subcellular
Location:** Cell membrane**— VALIDATION IMAGES —**

25 ug total protein per lane of various lysates (see on figure) probed with CD11c monoclonal antibody, unconjugated (bsm-61135R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD11c Monoclonal Antibody, Unconjugated(bsm-61135R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD11c Monoclonal Antibody, Unconjugated(bsm-61135R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.

— SELECTED CITATIONS —

- **[IF=6.4]** Mengdi Zhang, et al. Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies. INT J PHARM-X. 2025 Jun;9:100316 IHC ;Mouse. 39898009